Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Sicklick, Jason K ^a   Leonard, Stephanie Y ^a   Babicky, Michele L ^a   Tang, Chih Min ^a   Mose, Evangeline S ^a   French, Randall P ^a   Jaquish, Dawn V ^a   Hoh, Carl K ^a   Peterson, Michael ^a   Schwab, Richard ^b   Lowy, Andrew M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

GIST; Imatinib; KIT; NOD scid; NOD scid gamma; PDX; Sarcoma; Targeted therapy

Indexed keywords

AGED; ANIMALS; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MICE; MICE, SCID; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893701269     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-41     Document Type: Article

References (44)

1. Reichardt P, et al. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol 2009, 36:290-301. 10.1053/j.seminoncol.2009.06.002, 19664490.
2. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch 2010, 456:111-127. 10.1007/s00428-010-0891-y, 20165865.
3. Agaram NP, et al. Novel V600E BRAF mutations in Imatinib-naive and Imatinib-resistant gastrointestinal stromal tumors. Genes Chrom Cancer 2008, 47:853-859. 10.1002/gcc.20589, 2902874, 18615679.
4. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) Comparison of two doses of Imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010, 28:1247-1253. 2834472, 20124181, Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST).
5. Buchdunger E, O'Reilly T, Wood J. Pharmacology of Imatinib (STI571). Eur J Cancer 2002, 38(Suppl 5):S28-S36.
6. Kingham TP, DeMatteo RP. Multidisciplinary treatment of gastrointestinal stromal tumors. Surg Clin North Am 2009, 89:217-233. 10.1016/j.suc.2008.10.003, 19186237.
7. Dematteo RP, et al. Adjuvant Imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104. 10.1016/S0140-6736(09)60500-6, 2915459, 19303137.
8. Debiec-Rychter M, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to Imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004, 40:689-695. 10.1016/j.ejca.2003.11.025, 15010069.
9. Heinrich MC, et al. Molecular correlates of Imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24:4764-4774. 10.1200/JCO.2006.06.2265, 16954519.
10. Agaram NP, et al. Pathologic and molecular heterogeneity in Imatinib-stable or Imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 2007, 13:170-181. 10.1158/1078-0432.CCR-06-1508, 17200352.
11. Prenen H, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to Imatinib mesylate. Clin Cancer Res 2006, 12:2622-2627. 10.1158/1078-0432.CCR-05-2275, 16638875.
12. Wardelmann E, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with Imatinib mesylate. Clin Cancer Res 2006, 12:1743-1749. 10.1158/1078-0432.CCR-05-1211, 16551858.
13. Demetri GD, et al. Efficacy and safety of Sunitinib in patients with advanced gastrointestinal stromal tumour after failure of Imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338. 10.1016/S0140-6736(06)69446-4, 17046465.
14. George S, et al. Clinical evaluation of continuous daily dosing of Sunitinib malate in patients with advanced gastrointestinal stromal tumour after Imatinib failure. Eur J Cancer 2009, 45:1959-1968. 10.1016/j.ejca.2009.02.011, 19282169.
15. Trent JC, et al. A Phase II study of dasatinib for patients with Imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 2011, I:Abstract #10006.
16. George S, et al. A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with Imatinib (IM) and sunitinib (SU). J Clin Oncol 2011, I:Abstract #10007.
17. Demetri GD, et al. Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least Imatinib (IM) and sunitinib (SU): GRID trial. J Clin Oncol 2012, 30:Abstract #LBA10008.
18. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011, 11:865-878.
19. Taguchi T, et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Invest J Tech Methods Pathol 2002, 82:663-665.
20. Tuveson DA, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001, 20:5054-5058. 10.1038/sj.onc.1204704, 11526490.
21. Prenen H, et al. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to Imatinib by small animal positron emission tomography. Anticancer Res 2006, 26:1247-1252.
22. Huynh H, et al. Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Therap 2009, 8:152-159.
23. Wang TB, Huang WS, Lin WH, Shi HP, Dong WG. Inhibition of KIT RNAi mediated with adenovirus in gastrointestinal stromal tumor xenograft. World J Gastroenterol: WJG 2010, 16:5122-5129.
24. Rubin BP, et al. A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 2005, 65:6631-6639. 10.1158/0008-5472.CAN-05-0891, 16061643.
25. Sommer G, et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 2003, 100:6706-6711. 10.1073/pnas.1037763100, 164511, 12754375.
26. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007, 7:118-130. 10.1038/nri2017, 17259968.
27. Ishikawa F, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain(null) mice. Blood 2005, 106:1565-1573. 10.1182/blood-2005-02-0516, 1895228, 15920010.
28. Shultz LD, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005, 174:6477-6489.
29. Quintana E, et al. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598. 10.1038/nature07567, 2597380, 19052619.
30. King M, et al. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol 2008, 126:303-314. 10.1016/j.clim.2007.11.001, 18096436.
31. Simpson-Abelson MR, et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol 2008, 180:7009-7018.
32. Feldman J, Goldwasser R, Mark S, Schwartz J, Orion I. A mathematical model for tumor volume evaluation using two-dimensions. J Appl Quant Methods 2009, 4:455-461.
33. Edris B, et al. Anti-KIT monoclonal antibody inhibits Imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci USA 2013, 110:3501-3506. 10.1073/pnas.1222893110, 3587280, 23382202.
34. Reynolds CP, Sun BC, DeClerck YA, Moats RA. Assessing growth and response to therapy in murine tumor models. Methods Mol Med 2005, 111:335-350.
35. Huynh AS, et al. Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PloS one 2011, 6:e20330. 10.1371/journal.pone.0020330, 3103544, 21647423.
36. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metast Rev 1998, 17:279-284.
37. Revheim ME, et al. Intermittent and continuous Imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol 2013, 52:776-782. 10.3109/0284186X.2013.770920, 3622233, 23480638.
38. Moriyama M, et al. Establishment and characterization of a novel xenograft model of human gastrointestinal stromal tumor in mice. Anticancer Res 2013, 33:175-181.
39. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Models Mechan 2008, 1:78-82.
40. Morioka CY, Saito S, Ohzawa K, Watanabe A. Homologous orthotopic implantation models of pancreatic ductal cancer in Syrian golden hamsters: which is better for metastasis research-cell implantation or tissue implantation?. Pancreas 2000, 20:152-157. 10.1097/00006676-200003000-00007, 10707930.
41. Sicklick JK, Lopez NE. Optimizing surgical and Imatinib therapy for the treatment of gastrointestinal stromal tumors. J Gastroint Surg 2013, 17(11):1997-2006.
42. Hidalgo M, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Therap 2011, 10:1311-1316.
43. Moro M, et al. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J Biomed Biotechnol 2012, 2012:568567. 3324927, 22547927.
44. Revheim ME, et al. Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice. Anticancer Res 2009, 29:4331-4336.